Innovators in Point of Care Diagnostics
About XING Technologies
XING Technologies is an Australian-based biotechnology company specialising in transformative diagnosis and monitoring technologies for cancer and disease. Its proprietary nanotechnologies are transforming the future practice of medicine and enabling personalised healthcare.
Ultra-fast COVID-19 test in the works in Australia
XING Technologies has designed a simple pregnancy dipstick test has received $1.5 million dollars from the State Government through the Palaszczuk Government's Industry Tech Fund to fast track the corona virus test.
XING Technologies has bio-engineered yeast molecules, coated with velcro-like particles that the virus sticks to and can detect whether a person is infected and contagious within 15 minutes. The technology known as XavTrap®, is a low-cost, rapid point-of-care test that has also recieved US$1 million funding from the US Government to reduce the spread of COVID-19.
XING Group Holdings has a clear vision in applying point-of-care diagnostic nanotechnologies to globally enhance healthcare systems. XING's service and product lines currently span from cancer care to rapid nucleic acid extraction, protein detection diagnostics, and nanoparticle capture agents to identify and prevent the spread of infectious diseases.
Enabling rapid, cost-effective diagnostics with the potential for point-of-care nucleic acid detection of disease
Utilizes nanotechnology to perform a comprehensive analysis of nucleic acids in urine, blood, saliva & biopsy material
Portable equipment requiring minimal technical expertise and training
Provides an accurate measurement less than 30 minutes
Can perform multiple tests at once
Adaptable to all pathogens (bacteria, viruses, fungi, parasites) and cancer
XING Genomic Services
Whole genome sequencing
Whole exome sequencing
Targeted gene panels
Patient cohort studies
XING Cancer Care
Guiding patients with their oncologists through cancer genomic testing to improve patient outcomes
Providing referring oncologists with ongoing information and support in cancer genomic testing and interpretation
Our XGP1000 Cancer Panel offers the most sophisticated genomic analysis in Australia
NATA ISO 15189 accredited
Expertise in translational genomics and precision medicine to expand offerings in monitoring, therapy recommendations, and disease prognosis